Ovarian Cancer | Specialty

Dr. Secord on the Role of PARP Inhibitors in Ovarian Cancer

February 9th 2020

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Novel PARP Combinations Boost Responses in Ovarian Cancer

February 9th 2020

Floor J. Backes, MD, discusses the latest advancements made in the treatment of patients with ovarian cancer and the ongoing research efforts that are being made with novel combinations.

Treatment Options Abound in Platinum-Sensitive Ovarian Cancer

February 8th 2020

In ovarian cancer, disease that returns within 6 months of treatment following platinum-based therapy is defined as platinum-sensitive.

Dr. Duska on Primary Debulking Surgery in Ovarian Cancer

February 8th 2020

Linda R. Duska, MD, discusses primary debulking surgery in ovarian cancer.

Expert: Frontline Maintenance With PARP Inhibition Should Be Standard in Ovarian Cancer

February 7th 2020

Maintenance treatment with PARP inhibitors should be the standard of care in the frontline setting for patients with ovarian cancer, Kathleen M. Moore, MD, said during a presentation at the 2020 Society of Gynecologic Oncology Winter Meeting.

Niraparib Emerges as a Frontline Maintenance Standard in Advanced Ovarian Cancer

February 6th 2020

Antonio González-Martín, MD, discusses the design and findings of the PRIMA trial in advanced ovarian cancer.

Frontline Veliparib Regimen Viable Approach in Advanced Ovarian Cancer

January 28th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the VELIA trial and the impact the results are going to have on the use of PARP inhibitors in ovarian cancer.

NICE Recommends Olaparib Maintenance in Relapsed, Platinum-Sensitive Ovarian Cancer

January 16th 2020

The National Institute for Health and Care Excellence has recommended the use of olaparib as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

PARP Inhibitors Gain Importance in Ovarian Cancer Lineup

January 15th 2020

PARP inhibitors are poised to acquire a stronger foothold in the frontline setting for advanced ovarian cancer, for which chemotherapy remains the backbone of treatment, according to a panel of gynecologic oncology experts who discussed the issue during an OncLive Peer Exchange® held during the European Society for Medical Oncology Congress 2019.

FDA Grants Priority Review to Olaparib Plus Bevacizumab as Frontline Maintenance in Ovarian Cancer

January 13th 2020

The FDA has granted a priority review designation to a supplemental new drug application for the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab.

Dr. Berger on Frontline Treatment Options in Newly Diagnosed Advanced Ovarian Cancer

January 11th 2020

Jessica Layne Berger, MD, discusses the frontline treatment options in newly diagnosed ovarian cancer.

HER2+ Breast Cancer: Future Treatment Landscape

January 11th 2020

Practical Advice on Treating HER2+ Metastatic Breast Cancer

January 11th 2020

Targeting HER2 Outside of Breast Cancer

January 11th 2020

Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC

January 11th 2020

Emerging Agents for HER2+ mBC: Targeted Therapeutics

January 11th 2020

Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials

January 11th 2020

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

January 11th 2020

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

January 11th 2020

HER2+ mBC: Study Design and Results of DESTINY-Breast01

January 11th 2020